Episode
A Strategic Turn from Obesity to Cancer
- Podcast
- The Bio Report
- Published
- Feb 18, 2026
- Duration seconds
- 1373
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/a-strategic-turn-from-obesity-to-cancer/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-bio-report-1092382/a-strategic-turn-from-obesity-to-cancer.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
When Amy Burroughs stepped in as CEO of Terns Pharmaceuticals, she not only had to fill a void created by the death of her predecessor, but also lead a strategic shift from an increasingly crowded area of metabolic disease to focus on its experimental therapy for chronic myeloid leukemia. The company’s allosteric BCR-ABL inhibitor binds to a different site on the fusion protein than most first- and second-generation tyrosine kinase inhibitors. The data have the company and its investors believing the drug can reset the bar for both efficacy and tolerability in a multibillion-dollar market. We spoke with Burroughs about reinventing the company, the decision to seek partners for non-core assets, and how she is charting a clear path toward a broader oncology future.